Potential economic viability of two proposed rifapentine-based regimens for treatment of latent tuberculosis infection

PLoS ONE

Volumn 6, Issue 7, 2011, Pages

  Holland, David P ^a   Sanders, Gillian D ^a   Hamilton, Carol D ^a,b   Stout, Jason E ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b FAMILY HEALTH INTERNATIONAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; RIFAPENTINE; DRUG DERIVATIVE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DIRECTLY OBSERVED THERAPY; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG SELF ADMINISTRATION; LATENT TUBERCULOSIS; MONOTHERAPY; PATIENT COMPLIANCE; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; UNITED STATES; BIOLOGICAL MODEL; COST BENEFIT ANALYSIS; DRUG ADMINISTRATION; ECONOMICS; HUMAN;

ANTITUBERCULAR AGENTS; COST-BENEFIT ANALYSIS; DRUG ADMINISTRATION SCHEDULE; HUMANS; ISONIAZID; LATENT TUBERCULOSIS; MODELS, BIOLOGICAL; PATIENT COMPLIANCE; RIFAMPIN; SELF ADMINISTRATION; UNITED STATES;

EID: 79960589362     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0022276     Document Type: Article

References (32)

1. Bush OB Jr, Sugimoto M, Fujii Y, Brown FA Jr, (1965) Isoniazid prophylaxis in contacts of persons with known tuberculosis. Second report. Am Rev Respir Dis 92: 732-740.
2. Comstock GW, (1962) Isoniazid prophylaxis in an undeveloped area. Am Rev Respir Dis 86: 810-822.
3. Egsmose T, Ang'awa JO, Poti SJ, (1965) The use of isoniazid among household contacts of open cases of pulmonary tuberculosis. Bull World Health Organ 33: 419-433.
4. Centers for Disease Control and Prevention (2000) Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR Recomm Rep 49: 1-51.
5. Centers for Disease Control and Prevention (2005) Guidelines for the investigation of contacts of persons with infectious tuberculosis: Recommendations from the National Tuberculosis Controllers Association and CDC. MMWR Recomm Rep 54: 1-47.
6. Holland DP, Sanders GD, Hamilton CD, Stout JE, (2009) Costs and cost-effectiveness of four treatment regimens for latent tuberculosis infection. Am J Respir Crit Care Med 179: 1055-1060.
7. Jasmer RM, Snyder DC, Saukkonen JJ, Hopewell PC, Bernardo J, et al. (2004) Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a cost-effectiveness analysis based on a multicenter clinical trial. Clin Infect Dis 38: 363-369.
8. Salpeter SR, Sanders GD, Salpeter EE, Owens DK, (1997) Monitored isoniazid prophylaxis for low-risk tuberculin reactors older than 35 years of age: a risk-benefit and cost-effectiveness analysis. Ann Intern Med 127: 1051-1061.
9. LoBue PA, Moser KS, (2003) Use of isoniazid for latent tuberculosis infection in a public health clinic. Am J Respir Crit Care Med 168: 443-447.
10. Menzies D, Dion MJ, Rabinovitch B, Mannix S, Brassard P, et al. (2004) Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months. Am J Respir Crit Care Med 170: 445-449.
11. Gordin F, Chaisson RE, Matts JP, Miller C, de Lourdes Garcia M, et al. (2000) Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health Organization, and the Centers for Disease Control and Prevention Study Group. JAMA 283: 1445-1450.
12. Nuermberger E, Tyagi S, Williams KN, Rosenthal I, Bishai WR, et al. (2005) Rifapentine, Moxifloxacin, or DNA Vaccine Improves Treatment of Latent Tuberculosis in a Mouse Model. Am J Respir Crit Care Med 172: 1452-1456.
13. Schechter M, Zajdenverg R, Falco G, Barnes GL, Faulhaber JC, et al. (2006) Weekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts. Am J Respir Crit Care Med 173: 922-926.
14. Sterling TR, (2010) The PREVENT TB Study (TB Trials Consortium Study 26): 3 months of once-weekly rifapentine+INH vs. 9 months of daily INH for treatment of latent TB infection: First report of results of a multi-center, randomized clinical trial.; Berlin, Germany.
15. Zhang T, Zhang M, Rosenthal IM, Grosset JH, Nuermberger EL, (2009) Short-course therapy with daily rifapentine in a murine model of latent tuberculosis infection. Am J Respir Crit Care Med 180: 1151-1157.
16. (1982) Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. International Union Against Tuberculosis Committee on Prophylaxis. Bull World Health Organ 60: 555-564.
17. Comstock GW, (1975) Frost revisited: the modern epidemiology of tuberculosis. Am J Epidemiol 101: 363-382.
18. Horsburgh CR Jr, (2004) Priorities for the treatment of latent tuberculosis infection in the United States. N Engl J Med 350: 2060-2067.
19. Moss AR, Hahn JA, Tulsky JP, Daley CL, Small PM, et al. (2000) Tuberculosis in the homeless. A prospective study. Am J Respir Crit Care Med 162: 460-464.
20. Lardizabal A, Passannante M, Kojakali F, Hayden C, Reichman LB, (2006) Enhancement of treatment completion for latent tuberculosis infection with 4 months of rifampin. Chest 130: 1712-1717.
21. Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, et al. (2006) An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 174: 935-952.
22. Benator D, Bhattacharya M, Bozeman L, Burman W, Cantazaro A, et al. (2002) Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial. Lancet 360: 528-534.
23. Centers for Disease Control and Prevention (2010) Reported tuberculosis in the United States, 2009.
24. Salpeter EE, Salpeter SR, (1998) Mathematical model for the epidemiology of tuberculosis, with estimates of the reproductive number and infection-delay function. Am J Epidemiol 147: 398-406.
25. Guo N, Marra CA, Marra F, Moadebi S, Elwood RK, et al. (2008) Health State Utilities in Latent and Active Tuberculosis. Value Health 11: 1154-1161.
26. Perry D, (2011) North Carolina Tuberculosis Control Program pharmacy data.
27. Burman WJ, Dalton CB, Cohn DL, Butler JR, Reves RR, (1997) A cost-effectiveness analysis of directly observed therapy vs self-administered therapy for treatment of tuberculosis. Chest 112: 63-70.
28. Snyder DC, Chin DP, (1999) Cost-effectiveness analysis of directly observed therapy for patients with tuberculosis at low risk for treatment default. Am J Respir Crit Care Med 160: 582-586.
29. Taylor Z, Marks SM, Rios Burrows NM, Weis SE, Stricof RL, et al. (2000) Causes and costs of hospitalization of tuberculosis patients in the United States. Int J Tuberc Lung Dis 4: 931-939.
30. Brown RE, Miller B, Taylor WR, Palmer C, Bosco L, et al. (1995) Health-care expenditures for tuberculosis in the United States. Arch Intern Med 155: 1595-1600.
31. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB, (1996) Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA 276: 1253-1258.
32. Horsburgh CR Jr, O'Donnell M, Chamblee S, Moreland JL, Johnson J, et al. (2010) Revisiting rates of reactivation tuberculosis: a population-based approach. Am J Respir Crit Care Med 182: 420-425.